Baxalta Gmbh

Baxter International Inc.

Baxter Healthcare Sa

Baxter Aktiengesellschaft

Immuno Aktiengesellschaft

Takeda Pharmaceutical Company Limited

Baxter Innovations Gmbh

Stichting Sanquin Bloedvoorziening

Other

Baxler Innovations Gmbh

Immuno Aktiengesllschaft

Technische Universitāt Wien

Hans-Peter Schwarz

Peter Turecek

Wolfgang Teschner

Alfred Weber

Peter Matthiessen

Azra Pljevljakovic

Harald Arno Butterweck

Johann J Eibl

Sonja Svatos

Ruth Madlener

Friedrich Scheiflinger

Hartmut Ehrlich

Katalin Varadi

Birgit Maria Reipert

Randolf Kerschbaumer

Bernhard Koelbl

Theresa Friederike Bauer

Friedrich Dorner

Gerhard Antoine

Klaus Zimmermann

Hanspeter Rottensteiner

Falko-Guenter Falkner

Miha Furlan

Bernhard Laemmle

Leopold Bruckschwaiger

Jutta Schreiner

Luigina Tagliavacca

Bernhard Fischer

Artur Mitterer

Thomas Gundinger

Helena Elisabeth Schaller-Gerritsen

Manfred Reiter

Wolfgang Mundt

Uwe Schlokat

Nebojsa Nikolic

Andrea Engelmaier

Heinz Anderle

Johanna Kindermann

Lucia Gnauer

Renate Den-Bouwmeester

Reinhard Grausenburger

Gerhard Poelsler

Daniel R Boggs

Richard J Johnson

Koenraad Mertens

Thomas R Kreil

Shawn F Bairstow

Sindhu Ramachandran

Patrick Küry

Hans Pannekoek

Jan Aart Van Mourik

Petrus Johannes Lenting

Hans-Peter Hartung

Nevena Tzekova

Corinna Hermann

Sebastian Bunk

Julia Nuernberger

Bernhard Kölbl

Lucia Hofbauer

Juergen Siekmann

Ludwig Pichler

Hendrik Coenraad Hemker

Gerda Redl

Suzette Lucette Beguin

Yendra Linnau

Kurt Schnecker

Eva-Maria Muchitsch

Ernst Hetzl

Patrick Gavit

Andreas Ivens

Julia Nürnberger

Laura Lei

Katharina Nora Steinitz

Paula Maria Wilhelmina Van Helden

Christian Lubich

H Peter Matthiessen

Wolfgang Sch&ouml;nhofer

Alexander Zaydenberg

Maria Sasgary

Maria Schuster

Katarzyna Olas

Brigitte Keil

Sylvia Peyrer-Heimstaett

Stefan Romeder-Finger

Irina Elovaara

Gerald Brachtl

Helena Elisabeth Gerritsen

Manfred Rieger

Dirk V&ouml;lkel

Silvia Neppl

Miguel Lozano-Molero

Eibl Johann

Lena Nitsch

Susan Weber

Ursula Mais-Paul

David M Gelmont

Julia Singer

Sandor Fritsch

Martina Marchetti-Deschmann

Methods are provided for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-parvo B19 immunoglobulin G. The methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-parvo B19 immunoglobulin G are also provided. Methods for treating parvo B19 infections by administration of plasma-derived IgG compositions highly enriched for anti-parvo B19 immunoglobulin G are also provided.

Human plasma-derived IGG preparation enriched in anti-parvo B19 natural IGGS

The present invention relates to formulations of ADAMTS13 with enhanced or desirable properties. As such, the invention provides liquid and lyophilized formulations of ADAMTS13 that are suitable for pharmaceutical administration. Among other aspects, the present invention also provides methods of treating various diseases and conditions related to VWF and/or ADAMTS13 dysfunction in a subject. Also provided herein are kits comprising ADAMTS13 formulations useful for the treatment of various diseases and conditions.

Stabilized liquid and lyophilized ADAMTS13 formulations

The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

Removal of serine proteases by treatment with finely divided silicon dioxide

The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

The present invention provides long-term stable pharmaceutical formulations of recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations.

Recombinant VWF formulations

The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.

Method to produce an immunoglobulin preparation with improved yield

The invention generally relates to methods of testing the effectiveness of a von Willebrand factor (VWF) in treating von Willebrand disease (VWD) in a subject comprising measuring VWF cleavage fragments in a blood sample from the subject before and after treatment. In particular, the invention relates to methods of measuring VWF cleavage fragments, wherein an increase in VWF cleavage fragments after the treatment indicates that endogenous a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in the subject is cleaving the VWF and wherein a decrease or absence of VWF cleavage fragments after the treatment indicates that endogenous ADAMTS13 in the subject is not cleaving the VWF.

Methods for testing effectiveness of a von Willebrand factor used in treating von Willebrand disease (VWD)

The present invention provides, among other aspects, methods for the manufacture of plasma-derived immunoglobulin G compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A&#x3b2;, anti-RAGE, and anti-&#x3b1;-synuclein antibodies). Advantageously, the methods provided do not affect the manufacturing processes or capabilities for producing plasma-derived IgG therapeutics. Plasma-derived IgG compositions that are highly enriched for anti-brain disease related protein antibodies (e.g., anti-A&#x3b2;, anti-RAGE, and anti-&#x3b1;-synuclein antibodies), as also provided here. Methods for the treatment of brain diseases and disorders by administration of plasma-derived IgG compositions highly enriched for anti-brain disease related protein antibodies (e.g., anti-A&#x3b2;, anti-RAGE, and anti-&#x3b1;-synuclein antibodies), are also provided.

Methods to produce a human plasma-derived IgG preparation enriched in brain disease-related natural iggs

The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival.

IgG stimulated remyelination of peripheral nerves

The invention generally relates to methods of measuring cleaved von Willebrand factor (VWF) fragments. More specifically, the invention relates to methods of measuring the ability of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) to cleave VWF in vivo. The invention also relates to methods of using various animal models which demonstrate ADAMTS13 activity similar to that of a human. The invention further relates to methods of measuring the cleavage products of rVWF in mammals, particularly in humans and in human plasma.

Methods of measuring adamts 13 activity

Growing community of inventors

Vienna, Austria

Hans-Peter Schwarz